BRPI0906094A2 - composto e método de tratamento de diabetes do tipo ii - Google Patents

composto e método de tratamento de diabetes do tipo ii

Info

Publication number
BRPI0906094A2
BRPI0906094A2 BRPI0906094A BRPI0906094A BRPI0906094A2 BR PI0906094 A2 BRPI0906094 A2 BR PI0906094A2 BR PI0906094 A BRPI0906094 A BR PI0906094A BR PI0906094 A BRPI0906094 A BR PI0906094A BR PI0906094 A2 BRPI0906094 A2 BR PI0906094A2
Authority
BR
Brazil
Prior art keywords
type
treatment method
diabetes compound
diabetes
compound
Prior art date
Application number
BRPI0906094A
Other languages
English (en)
Inventor
Ting-Yueh Tsai
Tsu Hsu
Weir-Torn Jiaang
Yu-Sheng Chao
Original Assignee
Nat Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Health Research Institutes filed Critical Nat Health Research Institutes
Publication of BRPI0906094A2 publication Critical patent/BRPI0906094A2/pt
Publication of BRPI0906094B1 publication Critical patent/BRPI0906094B1/pt
Publication of BRPI0906094B8 publication Critical patent/BRPI0906094B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
BRPI0906094A 2008-03-05 2009-02-25 composto BRPI0906094B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3387708P 2008-03-05 2008-03-05
PCT/US2009/035111 WO2009111239A2 (en) 2008-03-05 2009-02-25 Pyrrolidine derivatives

Publications (3)

Publication Number Publication Date
BRPI0906094A2 true BRPI0906094A2 (pt) 2016-07-05
BRPI0906094B1 BRPI0906094B1 (pt) 2019-11-12
BRPI0906094B8 BRPI0906094B8 (pt) 2021-05-25

Family

ID=41054296

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906094A BRPI0906094B8 (pt) 2008-03-05 2009-02-25 composto

Country Status (16)

Country Link
US (1) US8022096B2 (pt)
EP (1) EP2252582B1 (pt)
JP (1) JP5586484B2 (pt)
KR (1) KR101634656B1 (pt)
CN (1) CN101970402B (pt)
AU (1) AU2009222198B2 (pt)
BR (1) BRPI0906094B8 (pt)
CA (1) CA2717518C (pt)
ES (1) ES2515194T3 (pt)
HK (1) HK1149261A1 (pt)
MY (1) MY155630A (pt)
NZ (1) NZ587911A (pt)
RU (1) RU2494094C2 (pt)
TW (1) TWI385163B (pt)
WO (1) WO2009111239A2 (pt)
ZA (1) ZA201006329B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2015DN03795A (pt) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
EP3116469B1 (en) 2014-03-10 2018-10-03 Mary Kay, Inc. Skin lightening compositions
CN104447478B (zh) * 2015-01-13 2016-04-13 佛山市赛维斯医药科技有限公司 一种含腈基金刚烷和酰胺结构的衍生物、其制备方法和用途
CN104496877B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种腈基金刚烷酰胺衍生物、其制备方法和用途
CN104478778B (zh) * 2015-01-13 2016-03-16 佛山市赛维斯医药科技有限公司 金刚烷酰胺类衍生物、其制备方法和用途
CN104447479B (zh) * 2015-01-13 2016-03-23 佛山市赛维斯医药科技有限公司 含金刚烷和酰胺类衍生物、其制备方法和用途
CN104529855B (zh) * 2015-01-13 2016-04-13 佛山市赛维斯医药科技有限公司 一种含羟基金刚烷和酰胺结构的衍生物、其制备方法和用途
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
WO2021136491A1 (zh) * 2019-12-31 2021-07-08 石药集团中奇制药技术(石家庄)有限公司 一种二肽基肽酶iv抑制剂的晶型及其制备方法和用途
CN114641277B (zh) * 2019-12-31 2023-06-13 石药集团中奇制药技术(石家庄)有限公司 一种二肽基肽酶4抑制剂的药物组合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293651T3 (es) 1995-11-28 2008-03-16 Cephalon, Inc. Inhibidores de cisteina y serina proteasas derivados de aminoacidos d.
JP2000264882A (ja) * 1999-03-18 2000-09-26 Nippon Shokubai Co Ltd 有機アミド化合物およびその製造方法
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
CN100430386C (zh) * 2002-11-07 2008-11-05 默克公司 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病
AU2003290577B2 (en) * 2002-11-07 2008-12-11 Merck Sharp & Dohme Corp. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004203526A (ja) 2002-12-24 2004-07-22 Sharp Corp 記録装置
PT1595866T (pt) 2003-01-31 2016-09-14 Sanwa Kagaku Kenkyusho Co Cianopirrolidinas úteis para o tratamento entre outras de síndrome metabólica
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
US20070093492A1 (en) 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
CN1942186B (zh) * 2004-03-09 2010-10-06 国家卫生研究院 吡咯烷化合物
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors

Also Published As

Publication number Publication date
MY155630A (en) 2015-11-13
US8022096B2 (en) 2011-09-20
HK1149261A1 (en) 2011-09-30
AU2009222198B2 (en) 2014-05-08
EP2252582A2 (en) 2010-11-24
EP2252582B1 (en) 2014-07-23
RU2010140627A (ru) 2012-04-10
BRPI0906094B8 (pt) 2021-05-25
AU2009222198A1 (en) 2009-09-11
US20090227569A1 (en) 2009-09-10
CN101970402B (zh) 2013-12-18
BRPI0906094B1 (pt) 2019-11-12
CN101970402A (zh) 2011-02-09
KR20100129754A (ko) 2010-12-09
ZA201006329B (en) 2011-05-25
TWI385163B (zh) 2013-02-11
EP2252582A4 (en) 2012-03-07
JP5586484B2 (ja) 2014-09-10
WO2009111239A3 (en) 2009-10-29
NZ587911A (en) 2012-02-24
WO2009111239A2 (en) 2009-09-11
KR101634656B1 (ko) 2016-06-29
ES2515194T3 (es) 2014-10-29
CA2717518A1 (en) 2009-09-11
TW200938530A (en) 2009-09-16
CA2717518C (en) 2017-03-21
JP2011513410A (ja) 2011-04-28
RU2494094C2 (ru) 2013-09-27

Similar Documents

Publication Publication Date Title
BRPI0906094A2 (pt) composto e método de tratamento de diabetes do tipo ii
LTPA2016041I1 (lt) Gydymo būdai panaudojant vaistus - amoniako gaudykles
BRPI0910854A2 (pt) métodos de tratamento
BRPI0910259A2 (pt) métodos de tratamento de inflamação
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0920284A2 (pt) composição e método
DK2405869T3 (da) Fedmebehandling
BRPI0910282A2 (pt) Composto oxadiazo-antraceno para o tratamento de diabetes
BRPI0919116A2 (pt) método
FI20075978A0 (fi) Järjestely ja menetelmä
BRPI0919575A2 (pt) método, e, composição
BRPI0810206A2 (pt) Método de tratar câncer
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
BRPI0917575A2 (pt) métodos de tratamento de talassemia
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
BRPI0823277A2 (pt) Composição, e , método
DK2313489T3 (da) Fremstillingsmetode
DK2330887T3 (da) Behandlingsindretning
DK2173831T3 (da) Brøndbehandling
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
DE502008000740D1 (de) Rollosystem
DK2361116T3 (da) Bestrålingsindretning
BRPI0917684A2 (pt) método terapêutico homeopático
BRPI0823238A2 (pt) Composição, e, método
BRPI0916597A2 (pt) Método

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF